Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liv
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as
| Condition(s) | Alcohol Use Disorder, Alcohol-associated Liver Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake. |
| Who can participate | Inclusion Criteria: * Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system. Exclusion Criteria: * Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease. |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Yale University |
| Locations | New Haven, Connecticut, United States |
| Start date | 2026-04-05 |
| NCT ID | NCT07525258 |
| Official listing | https://clinicaltrials.gov/study/NCT07525258 |